Psychopathology

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024
Depression, Patient, Mitochondrion, Doctor of Science, Harvard University, Therapy, Research, Risk, Mental health, University of Pittsburgh, Brain, DSM-IV codes, Brown University, Cannabis, Memory, Safety, Spectrum, Mitophagy, Schizophrenia, Hippocampus, Bipolar disorder, Anxiety, Learning, University, Psychopathology, Cerebrospinal fluid, University of California, Distinguishing, PET, Biomarker, Hope, Baylor College of Medicine, Behavior, AMPA, Fragile X syndrome, PTSD, Pharmaceutical industry

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

Black men’s mental health concerns are going unnoticed and unaddressed

Retrieved on: 
Wednesday, February 7, 2024
PTSD, Police, Anxiety, Attention, Crime, Social exclusion, Fear, Research, Housing, Racism by country, Psychopathology, Trauma, Injury, Skin, Depression, Employment, Mental health, Black studies, Economics, City, Perception, Stereotype, Education, University, Face, Nursing

A lawyer for his family said that he was dealing with a mental health crisis and was not a threat to anyone.

Key Points: 
  • A lawyer for his family said that he was dealing with a mental health crisis and was not a threat to anyone.
  • The incident also shines a light on the mental health concerns among Black men, which too often go unnoticed and unaddressed.
  • There seems to be a lack of urgency to address the mental health concerns of Black men in Canada, which can result in horrifying and deadly encounters with police.

Anti-Blackness as a mental health concern

  • Discussing mental health concerns is important, but we should avoid seeing them as a monolith.
  • Specific mental health concerns can impact a person’s physical and emotional well-being differently, but also their ability to recover and rehabilitate.
  • Although challenges with mental health can impact anyone, we must recognize that dealing with specific mental health issues can be uniquely different, and recovery and treatment can vary between people.

Black men and mental health

  • These feelings and negative stereotypical notions of Black masculinity can hinder Black men and boys’ ability to develop healthy perceptions of themselves and other Black men and boys.
  • The constant pressures Black men and boys face from negative police encounters leads many to avoid police.
  • This lack of engagement leaves mental illnesses among Black men and boys unresolved and reoccurring.
  • Consequently, Black men and boys who are suffering from mental health concerns will more likely have negative encounters with police.

Recognizing Black men’s suffering

  • As a result of stereotyping and social ostracization, there has been a sustained misunderstanding and misconception of Black men and boy’s lived experiences.
  • Recognizing the unique obstacles Black men and boys face is the first step toward this engagement.


Warren Clarke does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

AHN Appoints Ewurama Sackey, MD, as Medical Director of Maternal-Infant Mental Health

Retrieved on: 
Tuesday, December 19, 2023
Psychiatry, Lead, Hospital, UCLA, Trauma, Pregnancy, Paul Sackey, Multimedia, Mental health, Adolescence, Caregiver, WBH, Psychopathology, Parent, Western Pennsylvania Hospital, MD, Doctor of Philosophy, AHN, Allegheny Health Network, Psychopharmacology, University, Patient, Anxiety, Nursing

PITTSBURGH, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.

Key Points: 
  • Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.
  • PITTSBURGH, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.
  • "Joining a health care organization that is nationally recognized for its parent-infant mental health program is incredibly invigorating," said Dr. Sackey.
  • The Alexis Joy D'Achille Center for Perinatal Mental Health at West Penn Hospital serves as the flagship location for the Women's Behavioral Health program.

Perinatal Mood Disorders, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, August 28, 2023
Medical Affairs Bureau, Pregnancy, Psychopathology, Consultant, Clinical trial, ICON, Deficit spending, Woman, Doctor of Philosophy, MD, Patient, Child, Drug development, Infant, Health, ICON PLC, Birth control, Nursing

TORONTO, Aug. 28, 2023 /PRNewswire-PRWeb/ -- Postpartum depression affects 14 percent of women and is unique in that it can be a devastating disease to both mother and child.

Key Points: 
  • In this free webinar, gain an overview of the perinatal period and its associated psychiatric conditions, focusing on perinatal mood disorders.
  • Register to gain insights into perinatal mood disorders, available therapies and clinical trial considerations from a multidisciplinary team in this webinar.
  • Register to gain insights into perinatal mood disorders, available therapies and clinical trial considerations from a multidisciplinary team in this webinar.
  • For more information, or to register for this event, visit Perinatal Mood Disorders .

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Retrieved on: 
Thursday, August 10, 2023
Columbia University, San Francisco, Patent, Intellectual property, Clarivate, Drug development, Psychopathology, Therapy, Central nervous system, University, Anxiety, University of California, San Francisco, Composition, Research, Biomarker, IP, CNS, History of the University of Maryland, College Park, Pain, Dementia, Investigational New Drug, Acquisition, FDA, United States patent law, Information services, SILO, IND, Alzheimer's disease, PTSD, Peptide, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™, a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development.

Key Points: 
  • Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development.
  • Silo Pharma engages in the acquisition, licensing, and development of intellectual property and technology rights from leading universities and researchers, including the use of psychedelic drugs.
  • “Our new agreement with Clarivate gives us the opportunity to step up our intellectual property and patent expansion efforts and reinforce protection for our novel assets under development,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • In 2023, year-to-date, Silo Pharma has been awarded 3 new patents and one patent extension:
    U.S. Patent 16/825,371, covering SPU-21 as a method of selectively targeting inflamed synovial tissue.

Brain & Behavior Research Foundation Honors Innovative Psychiatric Researchers

Retrieved on: 
Monday, July 31, 2023
Cognition, Psychopathology, DSM-IV codes, Palpitations, Aggression, Research, Brain, Dopamine, Brain & Behavior Research Foundation, Gerald Klerman, Neuropsychiatry, Pain, Physician, Risk, Spectrum, Serotonin, Hunger, Psychiatry, Mental health, Irritability, Bipolar disorder, Behavior, Pharmaceutical industry, Dietary supplement

New York, July 31, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced the winners of its 2023 Klerman and Freedman Prizes, recognizing exceptional clinical and basic research in mental illness.

Key Points: 
  • New York, July 31, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced the winners of its 2023 Klerman and Freedman Prizes, recognizing exceptional clinical and basic research in mental illness.
  • “We applaud these researchers for their innovative thinking and extraordinary accomplishments across the field of neuropsychiatry, and we thank our generous donors for supporting scientists in brain and behavior research.”
    The prizewinners are selected by the BBRF Scientific Council comprised of 184 pre-eminent mental health researchers.
  • Since its founding in 1987, the Foundation has awarded more than $440 million to more 5,300 scientists around the world.
  • Five scientists received recognition for their outstanding work in brain and behavior research:
    Dr. Hafeman’s research focuses on youth diagnosed with or who are at risk for bipolar disorder.

First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine

Retrieved on: 
Tuesday, July 25, 2023
Anorexia nervosa, CMPS, Psychopathology, DRS, University, Nature Medicine, Mental health, Patient, Female, Safety, Pharmaceutical industry

Walter Kaye and Stephanie Knatz Peck at the University of California San Diego School of Medicine and is believed to be the first clinical research study to report the effects of psilocybin treatment in anorexia nervosa.

Key Points: 
  • Walter Kaye and Stephanie Knatz Peck at the University of California San Diego School of Medicine and is believed to be the first clinical research study to report the effects of psilocybin treatment in anorexia nervosa.
  • The study investigated the safety, efficacy, and tolerability of a single 25mg dose of COMP360 psilocybin, with psychological support (referred to as "psilocybin therapy" in the paper), in female patients with anorexia nervosa (n=10).
  • This study shows promising preliminary evidence that COMP360 psilocybin treatment could help people living with this difficult-to-treat condition.
  • We’re pleased to have conducted one of the first studies of psilocybin treatment in anorexia nervosa, and for our study to be published in one of the world’s leading peer-reviewed publications.

Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Retrieved on: 
Tuesday, May 9, 2023
Columbia University, Patent, Psychopathology, Therapy, Efficacy, Research, Biomarker, IP, SILO, Alzheimer's disease, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.  (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.” The new patent claims cover the use of biomarkers in determining the efficacy of the Company’s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology.

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.  (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.” The new patent claims cover the use of biomarkers in determining the efficacy of the Company’s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology.
  • “This patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological treatments and measure efficacy,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “Based on our latest research with Columbia University on SPC-15, this IP expands the claims of the original patent.”
    Silo Pharma owns an option to license certain assets of which the patent forms a part currently undergoing studies at Columbia University for stress-induced affective disorders and Alzheimer's disease.

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, February 28, 2023
Manic, N-255 National Highway, University of Zurich, Safety, Society, COMPASS, Biological Psychiatry (journal), COMP, University, Research, Webcast, Patient, R, Psilocybin, Pivotal, Anorexia nervosa, Science, CMPS, Mental health, G&A, Psychopathology, Suicidal ideation, Pharmaceutical industry, Medical device, Cryptocurrency, Lancet

LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business.

Key Points: 
  • LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business.
  • The COMPASS Pathways management team will host a conference call at 8.00am ET (1:00pm UK) on February 28, 2023.
  • A live webcast of the call will be available on COMPASS Pathway’s website at: Fourth Quarter and Year End 2022 Financial Results.
  • The call will also be webcast on the COMPASS Pathways website and archived for 30 days.

Vibrant Emotional Health Names Dr. Tia Dole as New Chief 988 Suicide & Crisis Lifeline Officer

Retrieved on: 
Saturday, January 28, 2023
General Health, Health, Mental Health, Well, Congressional Black Caucus, Executive, LGBTQ, Psychopathology, The Trevor Project, American Foundation for Suicide Prevention, Columbia University, Fordham University, Mental, Forensic psychology, National Suicide Prevention Week, Vibrant consonant, Developmental psychopathology, Dole, Multimedia, Mental health, Nursing, Lifeline

Vibrant Emotional Health (Vibrant), the nonprofit administrator of the National 988 Suicide & Crisis Lifeline (988 Lifeline), announced the appointment of Dr. Tia Dole as Chief 988 Suicide & Crisis Lifeline Officer, reporting to Kimberley Williams, President & CEO.

Key Points: 
  • Vibrant Emotional Health (Vibrant), the nonprofit administrator of the National 988 Suicide & Crisis Lifeline (988 Lifeline), announced the appointment of Dr. Tia Dole as Chief 988 Suicide & Crisis Lifeline Officer, reporting to Kimberley Williams, President & CEO.
  • Additionally, Dr. Dole served as the Chief Clinical Operations Officer at The Trevor Project, the world's largest suicide prevention and crisis intervention organization for LGBTQ youth.
  • Dole is a leader in the mental health field and brings a wealth of experience to Vibrant and to the 988 Lifeline as we continue to expand and deliver lifesaving services to those who contact the line,” said Kimberly Williams, President & CEO of Vibrant Emotional Health.
  • “I am honored to be joining Vibrant and the 988 Lifeline at this important and transformational time," said Dr. Dole.